For people with Type 1 diabetes, a life free from injections and 24/7 monitoring of their blood glucose levels may seem only a fantasy, but an Indianapolis-based biotech company believes relief could come in pill form. Toralgen Inc. is developing a drug delivery technology it says can take existing drugs that have to be injected and transform them into oral medications.
Indianapolis-based Toralgen Inc. says it has raised nearly $2 million in seed funding for what the company calls its transformative drug delivery tool. The biotechnology firm is attempting to commercialize a nanopill system, a microscopic-sized dose of medication, for diabetes control and other diseases.
INDIANAPOLIS, Ind. (September 10, 2019) – – Toralgen, Inc., an Indiana-based biotechnology company, announced the closure of its seed funding round, raising more than $1.9 million. Participants in the round include VisionTech Angels, Elevate Ventures, and Solyco Advisors as well as investors and strategic partners with deep domain expertise. Toralgen is a preclinical stage company focused on improving drug delivery and will use the funds to further development of their innovative platform.